146 related articles for article (PubMed ID: 38745021)
1. Transcriptomic characteristics according to tumor size and SUV
Ju SH; Lee SE; Yi S; Choi NR; Kim KH; Kim SM; Koh JY; Kim SK; Kim SY; Heo JY; Park JO; Park S; Koo BS; Kang YE
Sci Rep; 2024 May; 14(1):11005. PubMed ID: 38745021
[TBL] [Abstract][Full Text] [Related]
2. Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.
Yoon S; An YS; Lee SJ; So EY; Kim JH; Chung YS; Yoon JK
Medicine (Baltimore); 2015 Dec; 94(48):e2063. PubMed ID: 26632889
[TBL] [Abstract][Full Text] [Related]
3. Relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose uptake in patients with papillary thyroid cancer.
Kaida H; Hiromatsu Y; Kurata S; Kawahara A; Hattori S; Taira T; Kobayashi M; Uchida M; Yamada K; Mihashi H; Umeno H; Kage M; Nakashima T; Hayabuchi N; Ishibashi M
Nucl Med Commun; 2011 Aug; 32(8):690-8. PubMed ID: 21606885
[TBL] [Abstract][Full Text] [Related]
4. A new method for segmentation of FDG PET metabolic tumour volume using the peritumoural halo layer and a 10-step colour scale. A study in patients with papillary thyroid carcinoma.
Jun S; Kim H; Nam HY
Nuklearmedizin; 2015; 54(6):272-85. PubMed ID: 26429587
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.
Ma B; Jiang H; Wen D; Hu J; Han L; Liu W; Xu W; Shi X; Wei W; Liao T; Wang Y; Lu Z; Wang Y; Ji Q
J Clin Endocrinol Metab; 2019 Sep; 104(9):3713-3725. PubMed ID: 30942873
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
7. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
8. The difference in relationship between 18F-FDG uptake and clinicopathological factors on thyroid, esophageal, and lung cancers.
Kaida H; Kawahara A; Hayakawa M; Hattori S; Kurata S; Fujimoto K; Azuma K; Hirose Y; Takamori S; Hiromatsu Y; Nakashima T; Fujita H; Kage M; Hayabuchi N; Ishibashi M
Nucl Med Commun; 2014 Jan; 35(1):36-43. PubMed ID: 24169686
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma.
Reyes I; Reyes N; Suriano R; Iacob C; Suslina N; Policastro A; Moscatello A; Schantz S; Tiwari RK; Geliebter J
Cancer Biomark; 2019; 24(1):71-83. PubMed ID: 30614796
[TBL] [Abstract][Full Text] [Related]
10. Identification and analysis of genes associated with papillary thyroid carcinoma by bioinformatics methods.
Zhang S; Wang Q; Han Q; Han H; Lu P
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30872410
[TBL] [Abstract][Full Text] [Related]
11. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
12. Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer.
Zhai T; Muhanhali D; Jia X; Wu Z; Cai Z; Ling Y
Endocrine; 2019 Dec; 66(3):573-584. PubMed ID: 31332712
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
14. Relationship Between
Chang JW; Park KW; Heo JH; Jung SN; Liu L; Kim SM; Kwon IS; Koo BS
World J Surg; 2018 Jan; 42(1):114-122. PubMed ID: 28808756
[TBL] [Abstract][Full Text] [Related]
15. The effect of TP53 and P21 gene polymorphisms on papillary thyroid carcinoma susceptibility and clinical/pathological features.
Heidari Z; Harati-Sadegh M; Arian A; Maruei-Milan R; Salimi S
IUBMB Life; 2020 May; 72(5):922-930. PubMed ID: 31895498
[TBL] [Abstract][Full Text] [Related]
16. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
Suh S; Kim YH; Goh TS; Jeong DC; Lee CS; Jang JY; Cha W; Han ME; Kim SJ; Kim IJ; Pak K
Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
[TBL] [Abstract][Full Text] [Related]
17. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
18. FOXE1 inhibits cell proliferation, migration and invasion of papillary thyroid cancer by regulating PDGFA.
Ding Z; Ke R; Zhang Y; Fan Y; Fan J
Mol Cell Endocrinol; 2019 Aug; 493():110420. PubMed ID: 31129275
[TBL] [Abstract][Full Text] [Related]
19. MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma.
Gierlikowski W; Broniarek K; Cheda Ł; Rogulski Z; Kotlarek-Łysakowska M
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199867
[TBL] [Abstract][Full Text] [Related]
20. Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and
Araz M; Soydal Ç; Özkan E; Akkuş P; Nak D; Küçük NÖ; Kır KM
Cancer Biother Radiopharm; 2021 Jun; 36(5):425-432. PubMed ID: 32379488
[No Abstract] [Full Text] [Related]
[Next] [New Search]
